Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25726630 | 0.93 | FAAH (0.35) | KCNA5KCNH2FAAH | |
| SCHEMBL26666923 | 0.92 | KCNA5 (0.32) | KCNA5KCNH2CTDSP1GOT1FAAH | |
| SCHEMBL26078437 | 0.90 | FAAH (0.39) | KCNH2FAAH | |
| SCHEMBL21661962 | 0.85 | FAAH (0.40) | KCNH2FAAH | |
| SCHEMBL20442236 | 0.85 | FAAH (0.40) | KCNH2FAAH | |
| SCHEMBL22308327 | 0.84 | FAAH (0.40) | KCNH2FAAH | |
| SCHEMBL12469850 | 0.83 | GOT1 (0.34) | KCNA5KCNH2CTDSP1GOT1FAAH | |
| SCHEMBL13848610 | 0.82 | FAAH (0.34) | KCNA5KCNH2CTDSP1GOT1FAAH | |
| SCHEMBL3030998 | 0.81 | KCNA5 (0.32) | KCNA5KCNH2CTDSP1GOT1FAAH | |
| SCHEMBL21360381 | 0.79 | NR1I2 (0.40) | KCNH2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | KCNA5 4402/4885KCNH2 3785/4885CTDSP1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.